Scott L. Tarriff
Net Worth
Last updated:
What is Scott L. Tarriff net worth?
The estimated net worth of Mr. Scott L. Tarriff is at least $37,647,607 as of 2 Nov 2023. He owns shares worth $1,734,521 as insider, has earned $21,913,086 from insider trading and has received compensation worth at least $14,000,000 in Eagle Pharmaceuticals, Inc..
What is the salary of Scott L. Tarriff?
Mr. Scott L. Tarriff salary is $1,400,000 per year as Founder, Pres, Chief Executive Officer & Director in Eagle Pharmaceuticals, Inc..
How old is Scott L. Tarriff?
Mr. Scott L. Tarriff is 65 years old, born in 1960.
What stocks does Scott L. Tarriff currently own?
As insider, Mr. Scott L. Tarriff owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Eagle Pharmaceuticals, Inc. (EGRX) | Founder, Pres, Chief Executive Officer & Director | 545,447 | $3.18 | $1,734,521 |
What does Eagle Pharmaceuticals, Inc. do?
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Scott L. Tarriff insider trading
Eagle Pharmaceuticals, Inc.
Mr. Scott L. Tarriff has made 27 insider trades between 2015-2023, according to the Form 4 filled with the SEC. Most recently he sold 10,694 units of EGRX stock worth $148,326 on 2 Nov 2023.
The largest trade he's ever made was exercising 124,804 units of EGRX stock on 28 Jun 2018. As of 2 Nov 2023 he still owns at least 545,447 units of EGRX stock.
Eagle Pharmaceuticals key executives
Eagle Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:
- Mr. Brian Joseph Cahill (56) Chief Financial Officer
- Mr. David M. Pernock (72) Executive Vice President of Operations
- Mr. Scott L. Tarriff (65) Founder, Pres, Chief Executive Officer & Director